Arctic Bioscience will publish its financial results for the half year 2022 on Thursday 25 August, at 08:00 CET.
The same day at 10:00 CET, the Company will host a webcast to present the results. Following the presentation, it will be opened for questions from the audience.
Date: Thursday 25 August 2022
Time: 10:00 CET
Format: Webcast and Q&A
Participants will be required to register to view the webcast and participate in the Q&A.
For further information, please contact:
Christer L. Valderhaug
CEO of Arctic Bioscience AS
Mobile: +47 920 84 601
Jone R. Slinning
CFO of Arctic Bioscience AS
Mobile: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.